Publication | Closed Access

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

Malignant Pleural MesotheliomaMedicinePhase Iii TrialPathologyPleural DiseaseCisplatin Versus CisplatinCancer TreatmentOncologyRadiation Oncology